CatalystMarker
← board

ISCO

distress 0/10 · well-funded / low risk
$0.25+47%today0% from 52w high
internationalstemcell.com33 employeesFounded 2001San Diego, CABiotechnology
Revenue
pre-revenue
Liquidity
$1M
Runway
9.5 yrs
Shares 1y
0%

Price & events

+56.3% over 6M
$0.14$0.20$0.25Jan 26Apr 26Jul 2669kfinancing: 8-K material_agreement (2026-07-16)
CatalystRating changeDilutionFinancingdashed = today
+47.1%
1D
+19.0%
1W
+47.1%
1M
+78.6%
3M
+56.3%
6M
+38.9%
1Y
+150.0%
2Y
-58.3%
5Y
-37.5%
All

Overview

Market Cap
$2.00M
Volume
18.63K
52 Week Range
$0.12 – $0.25
Total Shares
8.00M
Float Shares
3.70M
% Held by Insiders
53.77%
% Held by Institutions
0.00%
RVOL
2.55x
Beta
0.00

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 8,004,389 · 0 offerings/1y · 0 PIPEs
  • 2026-07-168-Kmaterial_agreement
  • 2025-09-168-Kmaterial_agreement
  • 2024-09-178-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.